MedTrace Logo

Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy

NCT02124447 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-07-10

No results posted yet for this study

Summary

This will be a 4-way comparison to prospectively evaluate the efficacy and patient tolerability of four commercially available bowel preparations among patients undergoing colonoscopy for screening and surveillance in a single tertiary academic medical center.

Conditions

  • Patients Undergoing Screening or Surveillance Colonoscopy

Interventions

DRUG

PEG+E

Split dose 4 liter polyethylene glycol with electrolytes

DRUG

PEG+Asc

Split dose 2 liter polyethylene glycol with ascorbic acid

DRUG

P+MC

Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid

DRUG

sulfate

Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-08-31
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02124447 on ClinicalTrials.gov